they'll want it closer to the $5 mark for uplisting imo.  IMO once the get rolling with the filings to the fda it could happen. a decent result on kev may even be enough to push it.  Big pharma wants to see it in black and white, not just a press release.  Once the pps is better the uplisting would just be a matter of acceptance, an easy transition imo.
That's just my thinking.